Intravenous pyelogram

Active Ingredient: Iodixanol

Indication for Iodixanol

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Diagnostic

For this indication, competent medicine agencies globally authorize below treatments:

Concentration 550/652 mg/ml - Volume 40-80 ml


Dosage regimens

Intravenous, between 22 grams iodixanol and 44 grams iodixanol, one dose.

Concentration 550/652 mg/ml - Volume 2-4 ml/kg


Dosage regimens

Intravenous, between 1,100 milligrams iodixanol and 1,956 milligrams iodixanol, one dose.

Detailed description

Children <7kg: 270/320 mg I/ml 2-4 ml/kg
Children >7kg: 270/320 mg I/ml 2-3 ml/kg

All doses depending on age, weight and pathology (max.50ml).

Active ingredient

Read more about Iodixanol

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.